Infections, Papillomavirus Clinical Trial
Official title:
A Phase II Double-Blind, Randomized, Dose-Comparison Study to Evaluate the Safety and Immunogenicity of MEDI-517, a Virus-Like Particle Vaccine Against Human Papillomavirus Types 16 and 18, in Healthy Adult Female Volunteers
Verified date | September 2016 |
Source | GlaxoSmithKline |
Contact | n/a |
Is FDA regulated | No |
Health authority | United States: Food and Drug Administration |
Study type | Interventional |
The purpose of this Phase II study is to provide data regarding the safety and
immunogenicity for a range of dose levels of MEDI-517 in women who are HPV-16/18
seronegative and negative for high-risk HPV DNA. The study is designed to evaluate safety
and immunogenicity data for MEDI-517 when formulated with either AS04 or aluminum hydroxide.
Extended follow-up will provide long-term immune response data.
This study was originally performed by MedImmune. However, GSK is now responsible for the
clinical development of the HPV vaccine.
Status | Completed |
Enrollment | 210 |
Est. completion date | September 2004 |
Est. primary completion date | September 2004 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | Female |
Age group | 18 Years to 30 Years |
Eligibility |
Inclusion Criteria: - Females 18 through 30 years of age (must not have reached the 31st birthday) - Unless previously surgically sterilized, agrees to use an effective method of birth control beginning 30 days before the first study injection and continuing through 60 days after the final study injection - Healthy by medical history and physical examination - Seronegative for HPV-16 and HPV-18 antibody by ELISA within 21 days of study entry - Cervical specimen negative for high-risk HPV DNA using the Digene Hybrid Capture® II HPV test (high-risk types Probe B) within 21 days of study entry - Normal Pap smear, using the Cytyc ThinPrep® Pap Test, within 21 days of study entry - No evidence of anogenital HPV lesions or no physical findings suggestive of other gynecologic pathogens on pelvic examination within 21 days of study entry - Agrees to no other experimental therapy or vaccines until 30 days after the last study injection - Written informed consent obtained from the volunteer Exclusion Criteria: - Acute illness or fever (oral temperature = 99.5°F [37.5°C]) at start of the study - History or clinical manifestations of significant medical or psychiatric disorder - Pregnant or lactating - Use of immunosuppressive medication within the previous 90 days or history of immunodeficiency - History of cancer - History of alcohol or drug abuse within the past 2 years - Abnormal laboratory values in the screening panel which in the opinion of the principal investigator are judged to be clinically significant - Receipt of immunoglobulin or blood products within 90 days prior to study entry - History of abnormal Pap smear (other than a single prior report of ASCUS or indeterminate Pap smear with a subsequent normal report) - Positive tests for hepatitis C antibody, hepatitis B surface antigen, or HIV-1 antibody - Any prior receipt of any vaccine (experimental or otherwise) for treatment or prophylaxis of genital warts or other papillomavirus related condition. Any treatment of genital warts or other papillomavirus related condition within 6 months of randomization (local therapy for common skin and/or plantar warts is allowed) - Previous administration of any components of the investigational vaccine - Receipt of any experimental vaccine within 90 days prior to entry into this study - Receipt of any experimental drug therapy within 30 days or five half-lives of the experimental drug (if the half-life is known), whichever is longer |
Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention
Country | Name | City | State |
---|---|---|---|
n/a |
Lead Sponsor | Collaborator |
---|---|
GlaxoSmithKline |
Descamps D, Hardt K, Spiessens B, Izurieta P, Verstraeten T, Breuer T, Dubin G. Safety of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine for cervical cancer prevention: a pooled analysis of 11 clinical trials. Hum Vaccin. 2009 May;5(5):332-40. Epub 2009 May 20. — View Citation
Giannini SL, Hanon E, Moris P, Van Mechelen M, Morel S, Dessy F, Fourneau MA, Colau B, Suzich J, Losonksy G, Martin MT, Dubin G, Wettendorff MA. Enhanced humoral and memory B cellular immunity using HPV16/18 L1 VLP vaccine formulated with the MPL/aluminium salt combination (AS04) compared to aluminium salt only. Vaccine. 2006 Aug 14;24(33-34):5937-49. Epub 2006 Jun 19. — View Citation
Verstraeten T, Descamps D, David MP, Zahaf T, Hardt K, Izurieta P, Dubin G, Breuer T. Analysis of adverse events of potential autoimmune aetiology in a large integrated safety database of AS04 adjuvanted vaccines. Vaccine. 2008 Dec 2;26(51):6630-8. doi: 10.1016/j.vaccine.2008.09.049. — View Citation
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Solicited adverse event rates (including injection site and systemic reactions) | For 7 days after each injection | ||
Primary | Unsolicited adverse event rates | For 30 days after each injection | ||
Primary | Serious adverse event rates | From first injection through 30 days after last injection | ||
Primary | Laboratory assessments (Biochemistry and Hematology parameters) | Study Days 0, 30 and 210 | ||
Primary | Vital signs (temperature, blood pressure, pulse rate, respiratory rate) | At the time of injection and 30 minutes after the injection | ||
Primary | Serum ELISA titers against HPV-16 and HPV-18 | 30 days after the third injection | ||
Secondary | Serum ELISA titers against HPV-16 and HPV-18 | Study Days 0, 7, 30, 60, 180, 210, and 360, and at 24, 36, and 48 months | ||
Secondary | Neutralization titers against HPV-16 and HPV-18 | Study Days 0, 60, 210 and 360 | ||
Secondary | Cell-mediated immunity by IL-5, IFN-? and lymphoproliferative assays | Study Days 0, 60, 210, and 360 | ||
Secondary | HPV-16 and HPV-18 ELISA and inhibitory ELISA | Study Days 0, 60, 210, and 360, and at 18, 24, 36, and 48 months | ||
Secondary | Cervical and vaginal ELISA titers against HPV-16 and HPV-18 | At Study Days 210 and 360 |
Status | Clinical Trial | Phase | |
---|---|---|---|
Terminated |
NCT01290393 -
Post-marketing Study to Assess the Safety of CERVARIX When Used in the United States and in Canada
|
||
Completed |
NCT00369824 -
Evaluation of Safety and Immunogenicity of Co-administering HPV Vaccine With Other Vaccines in Healthy Female Subjects
|
Phase 3 | |
Completed |
NCT00345878 -
Study to Evaluate the Immune Response and Safety of GSK Biologicals' HPV Vaccine in Healthy Women Aged 18-35 Years
|
Phase 3 | |
Completed |
NCT00947115 -
Evaluation of Long-term Immunogenicity and Safety of a Human Papillomavirus (HPV) Vaccine in Healthy Female Subjects
|
Phase 3 | |
Completed |
NCT01187927 -
Drug Use Investigation for Cervarix®
|
N/A | |
Completed |
NCT00169494 -
Human Papilloma Virus Vaccine Consistency and Non-inferiority Trial in Young Adult Women With GSK Bio HPV-16/18
|
Phase 3 | |
Completed |
NCT01190176 -
Gynaecological Follow-up of a Subset of HPV-015 (NCT00294047) Study Subjects
|
Phase 3 | |
Completed |
NCT00359619 -
Human Papillomavirus Vaccine Immunogenicity and Safety Trial in Young Adult Women With GSK Biologicals Novel HPV Vaccine
|
Phase 2 | |
Completed |
NCT00196937 -
Human Papilloma Virus (HPV) Vaccine Immunogenicity and Safety Trial in Young and Adult Women With GSK Biologicals' HPV-16/18
|
Phase 3 | |
Completed |
NCT00534638 -
Effectiveness, Safety and Immunogenicity of GSK Biologicals' HPV Vaccine GSK580299 (Cervarix) Administered in Healthy Adolescents
|
Phase 4 | |
Completed |
NCT00250276 -
Evaluation of the Immune Responses of GSK Biologicals' HPV Vaccine Following Manufacturing Process Adaptation.
|
Phase 3 | |
Completed |
NCT01031069 -
Evaluation of Safety and Immunogenicity of a Human Papillomavirus (HPV) Vaccine in Human Immunodeficiency Virus (HIV) Infected Females
|
Phase 4 | |
Completed |
NCT00996125 -
Immunogenicity and Safety Study of GSK Biologicals' Human Papillomavirus 580299 Vaccine in Healthy Female Subjects
|
Phase 3 | |
Completed |
NCT00779766 -
Efficacy, Immunogenicity and Safety of GSK Biologicals' HPV GSK 580299 Vaccine in Healthy Chinese Female Subjects
|
Phase 3 | |
Completed |
NCT01953822 -
Study Assessing Risk of Autoimmune Diseases in Females (9 - 25 Years) Exposed to Cervarix® in United Kingdom
|
N/A | |
Completed |
NCT01153906 -
Post-marketing Safety Study of Autoimmune Diseases Following Cervarix® Vaccination
|
N/A | |
Completed |
NCT01207999 -
Type Distribution of Human Papillomavirus in Adult African Women Diagnosed With Invasive Cervical Cancer
|
N/A | |
Completed |
NCT00693615 -
Safety and Immunogenicity Study of MEDI-517 (GSK 580299) With or Without Adjuvant in Healthy Adult Females
|
Phase 2 | |
Completed |
NCT00541970 -
Partially Blind Study to Evaluate Immunogenicity & Safety of GSK Bio's HPV Vaccine 580299 in Healthy Women Aged 9-25 Yrs
|
Phase 1 | |
Completed |
NCT01627561 -
Safety and Immunogenicity of GSK Biologicals' HPV-16/18 L1 VLP AS04 Vaccine (GSK-580299) in Healthy Female Children 4-6 Years Old
|
Phase 3 |